Thus, genetic evidence from knockout animal studies suggests that inactivation of Cbl-b, as a non-redundant negative regulator of effector CD8+ T cell signaling, represents a rational approach to improve anti-cancer T cell reactivity in vivo. This evidence concerns the gene CBLB and cancer.